

**Amendments to the Claims:**



**Listing of Claims**

This listing of claims replaces all prior versions, and listings, of claims in the application.

Please amend Claims 57, 62, 64, 66, 70, 78- 80, 85, 91, 100 and 101 as follows:

**Claim 56 (Previously Presented)** A solid oral dosage form comprising

(a) a compound of the formula (I) or (II):



wherein

m is an integer from 0 to 1;

with the proviso that if m is 0 or 1, then

“HET” in the compound of formula (II) is a stable five- or six-membered monocyclic aromatic ring system composed of carbon atoms and one heteroatom, wherein the heteroatom is selected from the group consisting of N, O and S which may occupy any position in the ring whereby the resulting ring system is stable;

A is selected from the group consisting of -C(O)-, SO<sub>2</sub> and CH<sub>2</sub>;

Y is selected from the group consisting of CH<sub>2</sub> and CH as part of an olefin;

X is selected from the group consisting of CH<sub>2</sub>, CH as part of an olefin, NR<sub>3</sub>, S and O;

Serial No.: 10/775,675  
Art Unit: 1624

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

Z is selected from the group consisting of N and CH;

R<sub>1</sub> is one to two substituents independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, aminoalkyl and nitro;

Ar is selected from naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>8</sub> alkyl, fluorinated C<sub>1</sub>-C<sub>8</sub> alkoxy, halogen, cyano, hydroxy, amino, nitro, C<sub>1</sub>-C<sub>4</sub> alkylamino and C<sub>1</sub>-C<sub>4</sub> dialkylamino (wherein the alkyl groups on the amino may be the same or different); or phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>8</sub> alkyl, fluorinated C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> aralkyl (wherein optionally the alkyl or aryl portions are independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio and hydroxyl), C<sub>1</sub>-C<sub>8</sub> aralkoxy (wherein optionally the alkoxy or aryl portions are independently substituted and the alkoxy portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio and hydroxyl), halogen, cyano, hydroxy, amino, nitro, C<sub>1</sub>-C<sub>8</sub> alkylamino, C<sub>1</sub>-C<sub>4</sub> dialkylamino (wherein the alkyl groups on the amino may be the same or different), (halo)<sub>1-3</sub>(C<sub>1</sub>-C<sub>8</sub>)alkylthio, C<sub>1</sub>-C<sub>8</sub> alkylsulfonyl, C<sub>1</sub>-C<sub>8</sub> alkylthio, C<sub>1</sub>-C<sub>8</sub> alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl) and phenyl (optionally substituted with from one to two substituents independently selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, fluorinated C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, cyano, hydroxy, amino, nitro, C<sub>1</sub>-C<sub>4</sub> alkylamino, C<sub>1</sub>-C<sub>4</sub> dialkylamino (wherein the alkyl groups on the amino may be the same or different), C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub> alkylthio, and C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl);

Serial No.: 10/775,675  
Art Unit: 1624

R<sub>2</sub> is selected from the group consisting of NR<sub>4</sub>COAr, NR<sub>4</sub>CO-heteroaryl, NR<sub>4</sub>Ar, CH=CH-Ar, CF=CH-Ar, CH=CF-Ar, CCl=CH-Ar, CH=CCl-Ar, CH=CH-heteroaryl, CF=CH-heteroaryl, CH=CF-heteroaryl, -CCl=CH-heteroaryl, CH=CCl-heteroaryl, OCH<sub>2</sub>-Ar, OCH<sub>2</sub>-heteroaryl, SCH<sub>2</sub>-Ar and NR<sub>4</sub>CH<sub>2</sub>Ar;

R<sub>3</sub> is selected from the group consisting of hydrogen, acyl, alkyl, alkoxycarbonyl, alkylsulfonyl and arylsulfonyl;

R<sub>4</sub> is selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>5</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

and pharmaceutically acceptable salts thereof; and

(b) pharmaceutically acceptable carriers.

**Claim 57 (Currently Amended).** The solid oral dosage form of Claim 56 wherein "HET" of formula II is selected from the group consisting of thiophene, furan, pyrrole and pyridine;

A is -C(O)-;

Ar is naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from trifluoromethyl, trifluoromethoxy, -NH-C<sub>1</sub>-C<sub>4</sub> alkyl and -N-(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub> (wherein the alkyl groups on the amino may be the same or different);


Serial No.: 10/775,675  
Art Unit: 1624

$R_2$  is  $NR_4COAr$ ;

$R_4$  is selected from the group consisting of hydrogen and methyl.

**Claim 58** (Previously Presented) The solid oral dosage form of Claim 56 wherein  $R_4$  is hydrogen.

**Claim 59** (Previously Presented) The solid oral dosage form of Claim 56 wherein the compound is of formula (III):



(III)

wherein

$Y$  is selected from the group consisting of  $CH_2$  and  $CH$  as part of an olefin;

$X$  is selected from the group consisting of  $CH_2$ ,  $CH$  as part of an olefin,  $NR_3$ ,  $S$  and  $O$ ;

with the proviso that if  $Y$  is  $CH$  as part of an olefin, then  $X$  is  $CH$  as part of an olefin;

$R_1$  is one to two substituents independently selected from the group consisting of hydrogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, halogen, amino  $C_1$ - $C_4$  alkyl, ~~oxo~~ and nitro;

$R_2$  is  $NHCOAr$ ;

$R_3$  is selected from the group consisting of hydrogen, acyl,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkylsulfonyl and arylsulfonyl;

Serial No.: 10/775,675

Art Unit: 1624

R<sub>5</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

and (b) a pharmaceutically acceptable carrier.

**Claim 60 (Previously Presented)**      The solid oral dosage form of Claim 59 wherein

Y is selected from the group consisting of CH<sub>2</sub> and CH as part of an olefin;

X is selected from the group consisting of CH<sub>2</sub>, CH as part of an olefin, O and S;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

A is -C(O)-;

Z is CH;

Ar is phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>8</sub> alkyl, fluorinated C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> aralkyl (wherein optionally the alkyl or aryl portions are independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio and hydroxyl), C<sub>1</sub>-C<sub>8</sub> aralkoxy (wherein optionally the alkoxy or aryl portions are independently substituted and the alkoxy portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio and hydroxyl), halogen, cyano, hydroxy, amino, nitro, C<sub>1</sub>-C<sub>8</sub> alkylamino, C<sub>1</sub>-C<sub>4</sub> dialkylamino (wherein the alkyl groups on the amino may be the same or different), (halo)<sub>1-3</sub>(C<sub>1</sub>-C<sub>8</sub>)alkylthio, C<sub>1</sub>-C<sub>8</sub> alkylsulfonyl, C<sub>1</sub>-C<sub>8</sub> alkylthio, C<sub>1</sub>-C<sub>8</sub> alkylsulfinyl, heteroaryl


Serial No.: 10/775,675

Art Unit: 1624

(optionally substituted with one to two substituents independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl) and phenyl (optionally substituted with from one to two substituents independently selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, fluorinated C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, cyano, hydroxy, amino, nitro, C<sub>1</sub>-C<sub>4</sub> alkylamino, C<sub>1</sub>-C<sub>4</sub> dialkylamino (wherein the alkyl groups on the amino may be the same or different), C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub> alkylthio, and C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl);

and (b) a pharmaceutically acceptable carrier.

**Claim 61 (Previously Presented)** A solid oral dosage form comprising (a) a compound of the formula (IV):



X is selected from the group consisting of CH<sub>2</sub>, S and O;

R<sub>1</sub> is one to two substituents independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, amino C<sub>1</sub>-C<sub>4</sub> alkyl and nitro;

R<sub>5</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;


R<sub>6</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, phenyl (wherein the phenyl is optionally substituted with from one to two substituents independently selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, fluorinated C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, cyano, hydroxy, amino, nitro, C<sub>1</sub>-C<sub>4</sub> alkylamino, C<sub>1</sub>-C<sub>4</sub> dialkylamino (wherein the alkyl groups on the amino may be the same or different), C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub> alkylthio, and C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl); aralkyl (wherein the alkyl or aryl portions are optionally independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio and hydroxyl), aralkoxy (wherein the alkoxy or aryl portions are optionally independently substituted and the alkoxy portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio and hydroxyl), heteroaryl (optionally substituted with one to two substituents independently selected from C<sub>1</sub>-C<sub>4</sub> alkyl and halogen), heteroaryl(C<sub>1</sub>-C<sub>8</sub>)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents selected from C<sub>1</sub>-C<sub>8</sub> alkyl), (halo)<sub>1-3</sub>(C<sub>1</sub>-C<sub>4</sub>)alkylthio and halogen; and R<sub>7</sub> is independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>6</sub> alkyl and combinations thereof, wherein R<sub>7</sub> represent one to four independently selected groups; and

(b) pharmaceutically acceptable carrier.

**Claim 62 (Currently Amended)**      The solid oral dosage form of claim 61 wherein the ~~additive~~ carrier is selected from the group consisting of diluents, granulating agents, lubricants, binders, glidants, and disintegrating agents.

**Claim 63 (Previously Presented)**      A solid oral dosage form comprising (a) a compound of formula (IVa):

Serial No.: 10/775,675  
Art Unit: 1624



Formula (IVa)

wherein

Y is selected from the group consisting of CH<sub>2</sub> and CH as part of an olefin;

X is selected from the group consisting of CH<sub>2</sub>, CH as part of an olefin, S and O;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

R<sub>5</sub> is one to two substituents independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups may be the same or different), trifluoromethyl and trifluoromethoxy; and

(b) pharmaceutically acceptable carrier.


**Claim 64 (Currently Amended)** The solid oral dosage form of claim ~~61~~ 63 wherein the ~~additive~~ carrier is selected from the group consisting of diluents, granulating agents, lubricants, binders, glidants, and disintegrating agents.



Serial No.: 10/775,675

Art Unit: 1624

**Claim 65 (Previously Presented)** A solid oral dosage form comprising (a) a compound of formula (I):



wherein

A is selected from the group consisting of -C(O)-, SO<sub>2</sub> and CH<sub>2</sub>;

Y is selected from the group consisting of CH<sub>2</sub> and CH as part of an olefin;

X is selected from the group consisting of CH<sub>2</sub>, CH as part of an olefin, NR<sub>3</sub>, S, O and SO<sub>2</sub>;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

Z is selected from the group consisting of N and CH;

R<sub>1</sub> is one to two substituents independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, aminoalkyl, and nitro;

R<sub>2</sub> is selected from the group consisting of NR<sub>4</sub>COAr, NR<sub>4</sub>CO-heteroaryl, NR<sub>4</sub>Ar, CH=CH-Ar, CF=CH-Ar, CH=CF-Ar, CCl=CH-Ar, CH=CCl-Ar, CH=CH-heteroaryl, CF=CH-heteroaryl, CH=CF-heteroaryl, -CCl=CH-heteroaryl, CH=CCl-heteroaryl, OCH<sub>2</sub>-Ar, OCH<sub>2</sub>-heteroaryl, SCH<sub>2</sub>-Ar and NR<sub>4</sub>CH<sub>2</sub>Ar;

R<sub>3</sub> is selected from the group consisting of hydrogen, acyl, alkyl, aralkyl, alkoxycarbonyl, alkylsulfonyl, fluorinated alkyl and arylsulfonyl;

Ar is selected from the group consisting of naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>8</sub> alkyl, fluorinated C<sub>1</sub>-C<sub>8</sub> alkoxy, halogen, cyano, hydroxy, amino, nitro, C<sub>1</sub>-C<sub>4</sub> alkylamino and C<sub>1</sub>-C<sub>4</sub> dialkylamino (wherein the alkyl groups on the amino may be the same or different); and phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>8</sub> alkyl, fluorinated C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> aralkyl (wherein the alkyl portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents selected from the group consisting of halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio and hydroxy), C<sub>1</sub>-C<sub>8</sub> aralkoxy (wherein the alkoxy portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents selected from the group consisting of halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio and hydroxy), halogen, cyano, hydroxy, amino, nitro, C<sub>1</sub>-C<sub>8</sub> alkylamino, C<sub>1</sub>-C<sub>4</sub> dialkylamino (wherein the alkyl groups on the amino may be the same or different), C<sub>1</sub>-C<sub>8</sub> alkylsulfonyl, C<sub>1</sub>-C<sub>8</sub> alkylthio, (halo)<sub>1-3</sub>(C<sub>1</sub>-C<sub>8</sub>)alkylthio, C<sub>1</sub>-C<sub>8</sub> alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl and halogen), heteroaryl(C<sub>1</sub>-C<sub>8</sub>)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, fluorinated C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, cyano, hydroxy, amino, nitro, C<sub>1</sub>-C<sub>4</sub> alkylamino, C<sub>1</sub>-C<sub>4</sub> dialkylamino (wherein the alkyl groups on the amino may be the same or different), C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub> alkylthio and C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl);

R<sub>4</sub> is selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>5</sub> is one to two substituents independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

and (b) a pharmaceutically acceptable carrier.

**Claim 66 (Currently Amended)** The solid oral dosage form of claim ~~64~~ 65 wherein the ~~additive~~ carrier is selected from the group consisting of diluents, granulating agents, lubricants binders, glidants, and disintegrating agents.

**Claim 67 (Previously Presented)** The solid oral dosage form of claim 65 wherein A is -C(O)-.

**Claim 68 (Previously Presented)** The solid oral dosage form compound of claim 65 wherein Z is CH.

**Claim 69 (Previously Presented)** The solid oral dosage form of claim 65 wherein R<sub>1</sub> is one to two substituents independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, and halogen.

**Claim 70 (Currently Amended)** The solid oral dosage form of claim ~~60~~ 65 wherein R<sub>1</sub> is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, chlorine, and fluorine.

**Claim 71 (Previously Presented)** The solid oral dosage form of claim 65 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>8</sub> alkyl, fluorinated C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> aralkyl (wherein the alkyl portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents independently selected from the group consisting of halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio and hydroxy), C<sub>1</sub>-C<sub>8</sub> aralkoxy (wherein the alkoxy portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents independently selected from the group consisting of halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylthio and hydroxy), halogen, cyano, hydroxy, amino, nitro, C<sub>1</sub>-C<sub>8</sub> alkylamino, C<sub>1</sub>-C<sub>4</sub>

dialkylamino (wherein the alkyl groups on the amino may be the same or different), C<sub>1</sub>-C<sub>8</sub> alkylsulfonyl, C<sub>1</sub>-C<sub>8</sub> alkylthio, (halo)<sub>1-3</sub>(C<sub>1</sub>-C<sub>8</sub>)alkylthio, C<sub>1</sub>-C<sub>8</sub> alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl and halogen), heteroaryl(C<sub>1</sub>-C<sub>8</sub>)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, fluorinated C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, cyano, hydroxy, amino, nitro, C<sub>1</sub>-C<sub>4</sub> alkylamino, C<sub>1</sub>-C<sub>4</sub> dialkylamino (wherein the alkyl groups on the amino may be the same or different), C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub> alkylthio and C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl).

**Claim 72 (Previously Presented)** The solid oral dosage form of claim 65 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>8</sub> alkyl, halogen, hydroxy, (halo)<sub>1-3</sub>(C<sub>1</sub>-C<sub>8</sub>)alkylthio, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen and hydroxy).

**Claim 73 (Previously Presented)** The solid oral dosage form of claim 65 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, halogen, hydroxy, (halo)<sub>1-3</sub>(C<sub>1</sub>-C<sub>4</sub>)alkylthio, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen and hydroxy).

**Claim 74 (Previously Presented)** The solid oral dosage form of claim 65 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, fluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, halogen, hydroxy

and (halo)<sub>1-3</sub>(C<sub>1</sub>-C<sub>4</sub>)alkylthio, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen and hydroxy).

**Claim 75 (Previously Presented)** The solid oral dosage form of claim 65 wherein R<sub>2</sub> is selected from the group consisting of NR<sub>4</sub>COAr, NR<sub>4</sub>CO-heteroaryl, NR<sub>4</sub>Ar, CH=CH-Ar, CF=CH-Ar, CH=CF-Ar, CCl=CH-Ar, CH=CCl-Ar, CH=CH-heteroaryl, CF=CH-heteroaryl, CH=CF-heteroaryl, -CCl=CH-heteroaryl, CH=CCl-heteroaryl and NR<sub>4</sub>CH<sub>2</sub>Ar.

**Claim 76 (Previously Presented)** The solid oral dosage form of claim 65 wherein R<sub>2</sub> is selected from NR<sub>4</sub>COAr.

**Claim 77 (Previously Presented)** The solid oral dosage form of claim 65 wherein R<sub>2</sub> is selected from NHCOAr.

**Claim 78 (Currently Amended)** The ~~compound~~ solid oral dosage of claim 65 wherein R<sub>3</sub> is selected from the group consisting of hydrogen, acyl, C<sub>1</sub>-C<sub>8</sub> alkyl, ar(C<sub>1</sub>-C<sub>8</sub>)alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy carbonyl, C<sub>1</sub>-C<sub>8</sub> alkylsulfonyl, fluorinated(C<sub>1</sub>-C<sub>8</sub>) alkyl and arylsulfonyl.

**Claim 79 (Currently Amended)** The ~~compound~~ solid oral dosage of claim 65 wherein R<sub>3</sub> is selected from the group consisting of hydrogen, acyl, C<sub>1</sub>-C<sub>4</sub> alkyl, ar(C<sub>1</sub>-C<sub>4</sub>)alkyl and trifluoro(C<sub>1</sub>-C<sub>4</sub>)alkyl.

**Claim 80 (Currently Amended)** The solid oral dosage form of claim ~~8~~ 65 wherein R<sub>3</sub> is selected from the group consisting of hydrogen, formyl, methyl, isopropyl, benzyl and trifluoroethyl.

**Claim 81 (Previously Presented)** The solid oral dosage form of claim 65 wherein  $R_5$  is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, chlorine, fluorine, hydroxy, dimethylamino and trifluoromethyl.

**Claim 82 (Previously Presented)** The solid oral dosage form of claim 61 wherein  $R_6$  is selected from the group consisting of hydrogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, phenyl (wherein the phenyl is optionally substituted with from one to two substituents independently selected from the group consisting of  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, fluorinated  $C_1$ - $C_4$  alkyl, fluorinated  $C_1$ - $C_4$  alkoxy, halogen, cyano, hydroxy, amino, nitro,  $C_1$ - $C_4$  alkylamino,  $C_1$ - $C_4$  dialkylamino (wherein the alkyl groups on the amino may be the same or different),  $C_1$ - $C_4$  alkylsulfonyl,  $C_1$ - $C_4$  alkylthio and  $C_1$ - $C_4$  alkylsulfinyl); heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of  $C_1$ - $C_4$  alkyl and halogen), heteroaryl( $C_1$ - $C_8$ )alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from  $C_1$ - $C_8$  alkyl), (halo)<sub>1-3</sub>( $C_1$ - $C_4$ )alkylthio and halogen.

**Claim 83 (Previously Presented)** The solid oral dosage form of claim 61 wherein  $R_6$  is selected from the group consisting of hydrogen,  $C_1$ - $C_4$  alkyl, phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, halogen and hydroxy), heteroaryl (optionally substituted with one to two substituents independently selected from  $C_1$ - $C_4$  alkyl), (halo)<sub>1-3</sub>( $C_1$ - $C_4$ )alkylthio and halogen.

**Claim 84 (Previously Presented)** The solid oral dosage form of claim 61 wherein  $R_6$  is selected from the group consisting of hydrogen, methyl, phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of methyl, methoxy, fluorine and hydroxy), thienyl (optionally substituted with methyl), difluoromethylthio, fluorine, chlorine and iodine.

**Claim 85** (Currently Amended) The ~~compound~~ solid oral dosage of claim 61 wherein R<sub>7</sub> is one to three substituents independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy and fluorinated C<sub>1</sub>-C<sub>6</sub> alkyl.

**Claim 86** (Previously Presented) The solid oral dosage form of claim 61 wherein R<sub>7</sub> is one to three substituents independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and fluorinated C<sub>1</sub>-C<sub>4</sub> alkyl.

**Claim 87** (Previously Presented) The solid oral dosage form of claim 61 wherein R<sub>7</sub> is one to three substituents independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> alkoxy and fluorinated C<sub>1</sub>-C<sub>2</sub> alkyl.

**Claim 88** (Previously Presented) The solid oral dosage form of claim 61 wherein R<sub>7</sub> is one to three substituents independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, methyl, methoxy and trifluoromethyl.

**Claim 89** (Previously Presented) The solid oral dosage form of Claim 56 selected from the group consisting of

10-[4-[[2-Biphenyl]carbonyl]amino]benzoyl]-10,11-dihydro-5H-piperidino[2,1-c][1,4]benzodiazepine;

10-[4-[[2-Biphenyl]carbonyl]amino]benzoyl]-10,11-dihydro-5H-(tetrahydropyridino)[2,1-c][1,4]benzodiazepine;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

Serial No.: 10/775,675  
Art Unit: 1624

(S)-2-(4-Hydroxyphenyl)-N-[3-chloro-4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;

(S)-2-Phenyl-4-hydroxy-N-[3-chloro-4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;

(S)-2-(3-Hydroxyphenyl)-N-[3-chloro-4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;

(S)-2-Phenyl-5-hydroxy-N-[3-chloro-4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;

(RS)-2-(4-Methyl-2-thienyl)-4-fluoro-N-[3-chloro-4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;

(RS)-2,6-Dimethyl-N-[3-chloro-4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;

(RS)-2,3-Dimethyl-N-[3-chloro-4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;

(RS)-2-(4-Methyl-phenyl)-N-[4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;

(R)-2-Phenyl-N-[3-chloro-4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;

(RS)-2-Phenyl-N-[3-methoxy-4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;



Serial No.: 10/775,675

Art Unit: 1624

(*RS*)-2-Phenyl-*N*-[2-methoxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3,4,5-Tetrafluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Chloro-5-trifluoromethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Fluoro-3-chloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(Difluoromethylthio)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[2-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

Serial No.: 10/775,675

Art Unit: 1624

(*RS*)-2-Methyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-methoxy-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-fluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(9-chloro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8,9-difluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-methyl-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

Serial No.: 10/775,675

Art Unit: 1624

(*RS*)-2-Phenyl-*N*-[4-(8-chloro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(8-fluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(10-methyl-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-3,5-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Iodo-3-methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-3,5-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-3-iodo-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(2-Fluoro-phenyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-*N*-[3-dimethylamino-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

Serial No.: 10/775,675  
Art Unit: 1624

and pharmaceutically acceptable salts thereof.

**Claim 90 (Previously Presented)** The solid oral dosage form of Claim 65 selected from the group consisting of

(*RS*)-2-(3-Thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Thienyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Thienyl)-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(2-Thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-2-thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-2-thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2,2-dioxo-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

Serial No.: 10/775,675

Art Unit: 1624

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-benzyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-formyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-isopropyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,6-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

Serial No.: 10/775,675

Art Unit: 1624

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[2-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[2-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-trifluoromethyl-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[2-methyl-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

Serial No.: 10/775,675  
Art Unit: 1624

(*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-(2,2,2-trifluoroethyl)-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3,4,5-Tetrafluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-3-chloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,6-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-3-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

Serial No.: 10/775,675

Art Unit: 1624

(*RS*)-2-Phenyl-4-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-4-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;



Serial No.: 10/775,675  
Art Unit: 1624

(*RS*)-2-Phenyl-4-methoxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-methoxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

and pharmaceutically acceptable salts thereof.

**Claim 91 (Currently Amended)** A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 4 56.

**Claim 92 (Previously Presented)** The method of Claim 91, wherein the condition is congestive heart failure.

**Claim 93 (Previously Presented)** The method of Claim 91, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

**Claim 94 (Previously Presented)** A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 65.

**Claim 95 (Previously Presented)** The method of Claim 94, wherein the condition is congestive heart failure.

**Claim 96 (Previously Presented)** The method of Claim 94, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

Serial No.: 10/775,675  
Art Unit: 1624

**Claim 97 (Previously Presented)** A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 61.

**Claim 98 (Previously Presented)** The method of Claim 97, wherein the condition is congestive heart failure.

**Claim 99 (Previously Presented)** The method of Claim 97, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

**Claim 100 (Currently Amended)** The ~~compound~~ solid dosage form of claim 89 wherein the compound is (*S*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide and pharmaceutically acceptable salts thereof.

**Claim 101 (Currently Amended)** The ~~compound~~ solid dosage form of claim 90 wherein the compound is (*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide and pharmaceutically acceptable salts thereof.